CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares gapped down prior to trading on Wednesday . The stock had previously closed at $31.91, but opened at $30.50. CSL shares last traded at $31.6550, with a volume of 802 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CSLLY. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Royal Bank Of Canada raised shares of CSL from a “hold” rating to a “moderate buy” rating in a report on Tuesday, September 15th. Finally, Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

CSL Stock Performance

The company has a current ratio of 2.21, a quick ratio of 0.97 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average is $26.79 and its 200 day moving average is $23.33.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.